Interferon-β1a modulates glutamate neurotransmission in the CNS through CaMKII and GluN2A-containing NMDA receptors

Massimiliano Di Filippo, Alessandro Tozzi, Sara Arcangeli, Antonio De Iure, Valentina Durante, Maria Di Gregorio, Fabrizio Gardoni, Paolo Calabresi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Interferons (IFNs) are widely expressed cytokines with antiviral and immune-modulating effects and have been utilised for the treatment of several human pathological conditions. In particular, the immune-modulatory drug IFN-β is utilized in the treatment of multiple sclerosis (MS), a chronic autoimmune and neurodegenerative disorder of the central nervous system (CNS). Although the effects of IFN-β on immune cells functions have been widely investigated, information about the ability of the drug to modulate neuronal transmission in the CNS is still largely lacking. The aim of this study was to investigate the ability of IFN-β1a to modulate excitatory synaptic transmission in the CNS. Whole cell patch-clamp electrophysiological recordings were performed in the nucleus striatum, one of the CNS grey matter structures that is prone to degenerate during the course of MS. We demonstrate that the drug IFN-β1a, independently from its known peripheral immune-modulating action, is able to directly modulate synaptic transmission. In particular, we demonstrated that IFN-β1a reduces the amplitude of striatal excitatory post-synaptic currents, indicating an inhibitory effect on glutamate neurotransmission, and in particular on its NMDA component. The inhibitory effect of IFN-β1a on striatal glutamate neurotransmission was found to be mediated by a novel post-synaptic mechanism requiring Ca2+, CaMKII and the GluN2A subunit of the NMDA receptor, without the involvement of the classic STAT1 pathway. The evidence of a novel neuro-modulating effect of IFN-β shed light on the mechanisms of action of the drug and on the complex bidirectional interaction occurring between the immune and the nervous system. This article is part of the Special Issue entitled 'Synaptopathy - from Biology to Therapy'.

Original languageEnglish
Pages (from-to)98-105
Number of pages8
JournalNeuropharmacology
Volume100
DOIs
Publication statusPublished - 2016

Fingerprint

Calcium-Calmodulin-Dependent Protein Kinase Type 2
N-Methyl-D-Aspartate Receptors
Synaptic Transmission
Interferons
Glutamic Acid
Central Nervous System
Corpus Striatum
Pharmaceutical Preparations
Multiple Sclerosis
N-Methylaspartate
Neurodegenerative Diseases
Nervous System
Interferon-gamma
Antiviral Agents
Immune System
Cytokines

Keywords

  • Glutamate
  • Interferon
  • Multiple sclerosis
  • Neurotransmission
  • NMDA

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Interferon-β1a modulates glutamate neurotransmission in the CNS through CaMKII and GluN2A-containing NMDA receptors. / Di Filippo, Massimiliano; Tozzi, Alessandro; Arcangeli, Sara; De Iure, Antonio; Durante, Valentina; Di Gregorio, Maria; Gardoni, Fabrizio; Calabresi, Paolo.

In: Neuropharmacology, Vol. 100, 2016, p. 98-105.

Research output: Contribution to journalArticle

Di Filippo, Massimiliano ; Tozzi, Alessandro ; Arcangeli, Sara ; De Iure, Antonio ; Durante, Valentina ; Di Gregorio, Maria ; Gardoni, Fabrizio ; Calabresi, Paolo. / Interferon-β1a modulates glutamate neurotransmission in the CNS through CaMKII and GluN2A-containing NMDA receptors. In: Neuropharmacology. 2016 ; Vol. 100. pp. 98-105.
@article{c3504b12ff434aabb4bab9f10d44a4ce,
title = "Interferon-β1a modulates glutamate neurotransmission in the CNS through CaMKII and GluN2A-containing NMDA receptors",
abstract = "Interferons (IFNs) are widely expressed cytokines with antiviral and immune-modulating effects and have been utilised for the treatment of several human pathological conditions. In particular, the immune-modulatory drug IFN-β is utilized in the treatment of multiple sclerosis (MS), a chronic autoimmune and neurodegenerative disorder of the central nervous system (CNS). Although the effects of IFN-β on immune cells functions have been widely investigated, information about the ability of the drug to modulate neuronal transmission in the CNS is still largely lacking. The aim of this study was to investigate the ability of IFN-β1a to modulate excitatory synaptic transmission in the CNS. Whole cell patch-clamp electrophysiological recordings were performed in the nucleus striatum, one of the CNS grey matter structures that is prone to degenerate during the course of MS. We demonstrate that the drug IFN-β1a, independently from its known peripheral immune-modulating action, is able to directly modulate synaptic transmission. In particular, we demonstrated that IFN-β1a reduces the amplitude of striatal excitatory post-synaptic currents, indicating an inhibitory effect on glutamate neurotransmission, and in particular on its NMDA component. The inhibitory effect of IFN-β1a on striatal glutamate neurotransmission was found to be mediated by a novel post-synaptic mechanism requiring Ca2+, CaMKII and the GluN2A subunit of the NMDA receptor, without the involvement of the classic STAT1 pathway. The evidence of a novel neuro-modulating effect of IFN-β shed light on the mechanisms of action of the drug and on the complex bidirectional interaction occurring between the immune and the nervous system. This article is part of the Special Issue entitled 'Synaptopathy - from Biology to Therapy'.",
keywords = "Glutamate, Interferon, Multiple sclerosis, Neurotransmission, NMDA",
author = "{Di Filippo}, Massimiliano and Alessandro Tozzi and Sara Arcangeli and {De Iure}, Antonio and Valentina Durante and {Di Gregorio}, Maria and Fabrizio Gardoni and Paolo Calabresi",
year = "2016",
doi = "10.1016/j.neuropharm.2015.06.009",
language = "English",
volume = "100",
pages = "98--105",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Interferon-β1a modulates glutamate neurotransmission in the CNS through CaMKII and GluN2A-containing NMDA receptors

AU - Di Filippo, Massimiliano

AU - Tozzi, Alessandro

AU - Arcangeli, Sara

AU - De Iure, Antonio

AU - Durante, Valentina

AU - Di Gregorio, Maria

AU - Gardoni, Fabrizio

AU - Calabresi, Paolo

PY - 2016

Y1 - 2016

N2 - Interferons (IFNs) are widely expressed cytokines with antiviral and immune-modulating effects and have been utilised for the treatment of several human pathological conditions. In particular, the immune-modulatory drug IFN-β is utilized in the treatment of multiple sclerosis (MS), a chronic autoimmune and neurodegenerative disorder of the central nervous system (CNS). Although the effects of IFN-β on immune cells functions have been widely investigated, information about the ability of the drug to modulate neuronal transmission in the CNS is still largely lacking. The aim of this study was to investigate the ability of IFN-β1a to modulate excitatory synaptic transmission in the CNS. Whole cell patch-clamp electrophysiological recordings were performed in the nucleus striatum, one of the CNS grey matter structures that is prone to degenerate during the course of MS. We demonstrate that the drug IFN-β1a, independently from its known peripheral immune-modulating action, is able to directly modulate synaptic transmission. In particular, we demonstrated that IFN-β1a reduces the amplitude of striatal excitatory post-synaptic currents, indicating an inhibitory effect on glutamate neurotransmission, and in particular on its NMDA component. The inhibitory effect of IFN-β1a on striatal glutamate neurotransmission was found to be mediated by a novel post-synaptic mechanism requiring Ca2+, CaMKII and the GluN2A subunit of the NMDA receptor, without the involvement of the classic STAT1 pathway. The evidence of a novel neuro-modulating effect of IFN-β shed light on the mechanisms of action of the drug and on the complex bidirectional interaction occurring between the immune and the nervous system. This article is part of the Special Issue entitled 'Synaptopathy - from Biology to Therapy'.

AB - Interferons (IFNs) are widely expressed cytokines with antiviral and immune-modulating effects and have been utilised for the treatment of several human pathological conditions. In particular, the immune-modulatory drug IFN-β is utilized in the treatment of multiple sclerosis (MS), a chronic autoimmune and neurodegenerative disorder of the central nervous system (CNS). Although the effects of IFN-β on immune cells functions have been widely investigated, information about the ability of the drug to modulate neuronal transmission in the CNS is still largely lacking. The aim of this study was to investigate the ability of IFN-β1a to modulate excitatory synaptic transmission in the CNS. Whole cell patch-clamp electrophysiological recordings were performed in the nucleus striatum, one of the CNS grey matter structures that is prone to degenerate during the course of MS. We demonstrate that the drug IFN-β1a, independently from its known peripheral immune-modulating action, is able to directly modulate synaptic transmission. In particular, we demonstrated that IFN-β1a reduces the amplitude of striatal excitatory post-synaptic currents, indicating an inhibitory effect on glutamate neurotransmission, and in particular on its NMDA component. The inhibitory effect of IFN-β1a on striatal glutamate neurotransmission was found to be mediated by a novel post-synaptic mechanism requiring Ca2+, CaMKII and the GluN2A subunit of the NMDA receptor, without the involvement of the classic STAT1 pathway. The evidence of a novel neuro-modulating effect of IFN-β shed light on the mechanisms of action of the drug and on the complex bidirectional interaction occurring between the immune and the nervous system. This article is part of the Special Issue entitled 'Synaptopathy - from Biology to Therapy'.

KW - Glutamate

KW - Interferon

KW - Multiple sclerosis

KW - Neurotransmission

KW - NMDA

UR - http://www.scopus.com/inward/record.url?scp=84942364609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942364609&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2015.06.009

DO - 10.1016/j.neuropharm.2015.06.009

M3 - Article

C2 - 26116817

AN - SCOPUS:84942364609

VL - 100

SP - 98

EP - 105

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

ER -